--News Direct--
Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell speaks to Proactive's Thomas Warner after announcing the dosing of the first patient in a new trial of the company's AT278 ultra-concentrated and rapid-acting insulin.
Howell explains what the trial means for Arecor as it works towards developing better solutions for people living with diabetes.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/arecor-therapeutics-gets-second-phase-1-trial-for-at278-underway-421044108
